Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18102338 | 0.77 | TSHR (0.64) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL22380663 | 0.77 | TSHR (0.64) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL22623766 | 0.74 | PSMD14 (0.44) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL3080998 | 0.74 | PSMD14 (0.77) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL791114 | 0.70 | — | — | |
| SCHEMBL14508243 | 0.70 | TSHR (0.46) | PSMD14TSHRHSD11B1 | |
| SCHEMBL13323568 | 0.67 | — | — | |
| SCHEMBL12040071 | 0.65 | — | — | |
| SCHEMBL22861645 | 0.64 | PSMD14 (0.38) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL23775714 | 0.62 | MAPT (0.39) | PSMD14HSD11B1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365570-A1 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230338311-A1 | SUPPRESSION OF INFLAMMASOME ACTIVATION | WASHINGTON UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230193328-A1 | METHOD TO PRODUCE THE ANTI-MICROBIAL DITERPENOID LEUBETHANOL AND RELATED SERRULATANE-TYPE DITERPENES | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-06-22 | — | — | US | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | OXFORD FINANCE LLC | 2023-05-04 | — | — | US | disclosed |
| EP-2603514-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9108920-B2 | Diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8623903-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20130289003-A1 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME LLC | 2013-10-31 | — | — | US | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8143285-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA | 2011-02-03 | — | — | US | disclosed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | PSMD14 1056/4885TSHR 2599/4885HSD11B1 3318/4885 |
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSME1, PSME4 | PSMD14 67/4885TSHR 4437/4885HSD11B1 2648/4885 |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | PSMD14 4570/4885TSHR 554/4885HSD11B1 792/4885 |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | PSMD14 637/4885TSHR 1013/4885HSD11B1 1478/4885 |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | PGF, PTGS1, PTGS2 | PSMD14 3339/4885TSHR 3096/4885HSD11B1 626/4885 |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, HRH2, PTGDR2 | PSMD14 1514/4885TSHR 657/4885HSD11B1 1169/4885 |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | PSMD14 1238/4885TSHR 1300/4885HSD11B1 3010/4885 |
| US-20130289003-A1 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | PGF, ALPP, PAH | PSMD14 4187/4885TSHR 2850/4885HSD11B1 255/4885 |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | STAT5A, STAT5B, STAT3 | PSMD14 1164/4885TSHR 1212/4885HSD11B1 2813/4885 |
| US-20230365570-A1 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | NR3C1, NR3C2, NR5A1 | PSMD14 4337/4885TSHR 1269/4885HSD11B1 17/4885 |
| US-20230338311-A1 | SUPPRESSION OF INFLAMMASOME ACTIVATION | NLRP3, IL1B, NOD2 | PSMD14 3133/4885TSHR 4461/4885HSD11B1 2205/4885 |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | PSMD14 1072/4885TSHR 499/4885HSD11B1 794/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | PSMD14 1456/4885TSHR 1093/4885HSD11B1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.